Siewert Type II Adenocarcinoma of Esophagogastric Junction Clinical Trials in Cleveland, Ohio

Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma